Previous 10 | Next 10 |
Compugen Ltd. (CGEN) Q1 2019 Results Earnings Conference Call May 20, 2019, 08:30 AM ET Company Participants Elana Holzman - Director, IR and Corporate Communications Anat Cohen-Dayag - President and CEO Ari Krashin - CFO and COO Henry Adewoye - CMO Conference Call Participa...
Compugen (NASDAQ: CGEN ) has dosed the first patient in the combination arm of its Phase 1 study, combining escalating doses of COM701 with a fixed dose of Opdivo (nivolumab) in patients with advanced solid tumors. More news on: Compugen Ltd., Healthcare stocks news, Read mor...
Compugen (NASDAQ: CGEN ): Q1 GAAP EPS of -$0.14 beats by $0.03 . More news on: Compugen Ltd., Earnings news and commentary, Healthcare stocks news, , Read more ...
HOLON, Israel , May 20, 2019 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a leader in predictive discovery and development of first-in-class therapeutics for cancer immunotherapy, today reported financial results for the first quarter ended March 31, 2019 . "2019 continues to ...
HOLON, Israel , May 20, 2019 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and leader in predictive target discovery, today announced that it has dosed the first patient in the combination arm of its Phase 1 study, combining escala...
HOLON, Israel , May 6, 2019 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a leader in predictive discovery and development of first-in-class therapeutics for cancer immunotherapy, announced today that the Company will release its first quarter 2019 financial results on Monday, May 20, ...
HOLON, Israel , April 3, 2019 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN ), a clinical-stage cancer immunotherapy company and leader in predictive target discovery, today announced that its ongoing Phase 1 clinical trial evaluating COM701, a first-in-class therapeutic ...
NEW YORK , March 26, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) ( www.oramed.com ), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that its Chinese partner, Hefei Tianhui Incu...
HOLON, Israel , March 26, 2019 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and leader in predictive target discovery, today announced that its entire board of directors and members of management purchased Company shares on the op...
The USPTO has granted two composition of matter patents for Compugen's (NASDAQ: CGEN ) COM701, lead immuno-oncology therapeutic antibody candidate. More news on: Compugen Ltd., Healthcare stocks news, Read more ...
News, Short Squeeze, Breakout and More Instantly...
Compugen Announces FDA Clearance of IND for COM503 for the Treatment of Solid Tumors PR Newswire FDA clearance triggers a $30 million milestone payment from Gilead Company on track to initiate a Phase 1 trial for COM503, a differentiated antibody approach to harne...
Compugen to Release Second Quarter 2024 Results on Tuesday, August 6, 2024 PR Newswire HOLON, Israel , July 23, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target ...
Compugen to Present at Upcoming Antibody Industrial Symposium PR Newswire HOLON, Israel , June 17, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, t...